Share-based Payment Arrangement, Expense of Quince Therapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Quince Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Quince Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,255,000, a 12% increase year-over-year.
  • Quince Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,039,000, a 15% decline year-over-year.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,746,000, a 9.1% decline from 2023.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,220,000, a 69% decline from 2022.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $16,618,000, a 44% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Quince Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,039,000 $1,255,000 +$131,000 +12% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $4,908,000 $1,273,000 +$50,000 +4.1% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $4,858,000 $1,386,000 +$112,000 +8.8% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $4,746,000 $1,125,000 -$1,183,000 -51% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $5,929,000 $1,124,000 -$207,000 -16% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $6,136,000 $1,223,000 +$1,123,000 +1123% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $5,013,000 $1,274,000 -$207,000 -14% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $5,220,000 $2,308,000 +$675,000 +41% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $4,545,000 $1,331,000 +$637,000 +92% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $100,000 -$4,951,000 -98% 04 Aug 2023 10-Q 13 May 2024 2024 Q1
Q2 2023 $3,908,000 $1,321,000 -$3,730,000 -74% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $8,859,000 $1,481,000 -$7,759,000 -84% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $16,618,000 $1,633,000 -$6,861,000 -81% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $23,479,000 $694,000 -$6,924,000 -91% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $30,403,000 $5,051,000 -$1,699,000 -25% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $32,102,000 $9,240,000 +$2,249,000 +32% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $29,853,000 $8,494,000 +$3,535,000 +71% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $26,318,000 $7,618,000 +$3,460,000 +83% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $22,858,000 $6,750,000 +$3,352,000 +99% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $19,506,000 $6,991,000 +$5,036,000 +258% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $14,470,000 $4,959,000 +$4,382,000 +759% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $10,088,000 $4,158,000 +$3,246,000 +356% 01 Jul 2020 30 Sep 2020 10-Q 29 Oct 2021 2021 Q3
Q2 2020 $6,842,000 $3,398,000 +$3,021,000 +801% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $3,821,000 $1,955,000 +$1,765,000 +929% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $2,056,000 $577,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $912,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $377,000 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $190,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1

Quince Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,746,000 -$474,000 -9.1% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $5,220,000 -$11,398,000 -69% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $16,618,000 -$13,235,000 -44% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $29,853,000 +$15,383,000 +106% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $14,470,000 +$12,414,000 +604% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $2,056,000 +$1,901,000 +1226% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $155,000 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.